Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Tailored medication preparation and ongoing education are crucial for effective treatments.

This study examines the use of diphenylcyclopropenone in treating alopecia areata patients at the University Hospital Würzburg and investigates how the treatment affects patients' quality of life.

This study found that sympathetic nerves and arrector pili muscles form a niche that modulates hair follicle stem cell activity, revealing their role in hair follicle regeneration.

This review revisits the mechanisms of wound induced hair follicle neogenesis in mice and concludes that the process involves canonical WNT signaling activated by Fgf9 from γδ T cells, but more research is needed to fully understand its cellular bases.

This study identified hair shaft progenitors in the matrix that regulate hair growth and pigmentation by creating a niche dependent on stem cell factor, implicating KROX20+ cells in these processes.

This article discusses how challenges in drug development and success rates are driving a shift in the pharmaceutical industry towards engineering targeted drug delivery systems, with nanomaterials offering potential solutions for selective therapeutic delivery.

This study concluded that the best approach for detecting Androsta-1,4,6-triene-3,17-dione administration in horses is monitoring the metabolites M1b or M4 in urine, detectable up to 77 hours post-administration.

This review examines various androgen deprivation therapy methods for advanced prostate cancer, highlighting benefits and potential cardiovascular and sexual adverse effects, but reports no new clinical results.

This study found that men receiving enzalutamide and other androgen-deprivation therapies may be at increased risk for QT prolongation and torsades de pointes.

This study demonstrated that adenosine triphosphate may prevent vandetanib-induced skin toxicity in rats, suggesting potential for further research in other animal models and humans.

The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.

This retrospective analysis reported significant increases in testosterone levels in men with testosterone deficiency using the Daily Subcutaneous Testosterone method combined with hCG and anastrozole, indicating its potential as a treatment option.

This content contains no study findings or new results, instead referring only to statistical methods and figure captions.

This study found that androsterone glucuronate (ADT-G) was the only androgenic metabolite sensitive to detecting differences between adult women with acne and controls, and its levels decreased with systemic treatment.

In this study, the authors highlight the potential of intradermal microinjections of dutasteride as an adjunctive therapy for androgenetic alopecia, though they note that information on its effectiveness remains limited.

In this study, both the topical minoxidil 7%/dutasteride 0.5 mg and topical minoxidil 7%/finasteride 1 mg treatments for androgenetic alopecia showed high effectiveness, but the dutasteride combination was associated with greater efficacy and more adverse effects.

This study found that dutasteride reduced β-amyloid plaque load in a cerebral amyloidosis model, seemingly linked to mitochondrial apoptosis and autophagy processes.

In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.

This article discusses the FDA approval of dutasteride for benign prostatic hypertrophy and explores its potential role in treating androgenetic alopecia but reports no new clinical findings.

This study found that dutasteride 0.5 mg was generally well-tolerated and led to overall improvement in male patients aged 18 to 41 with androgenic alopecia in a Korean clinical practice setting.

This article reviews antibody drug conjugates for cancer treatment, describing their mechanism, recent approvals, and ongoing research efforts, but reports no new clinical results.

In this study, researchers addressed the limitations of adenosine's practical application in treating inflammation, oxidative stress, and tissue repair due to its poor water solubility and low transdermal permeability. Results are not reported in the abstract.

This source reports that trastuzumab deruxtecan improves outcomes in HER2-positive and HER2-low metastatic breast cancer, emphasizing the need for careful adverse event monitoring, particularly for interstitial lung disease, and managing emetic risk to maximize benefits.

This study found that androgen deprivation therapy is associated with an increased risk of acquired long-QT syndrome and Torsades de Pointes, particularly highlighting enzalutamide's greater association with sudden death compared to other therapies.

This study observed that both finasteride and dutasteride significantly decreased dihydrotestosterone concentrations in hair, with dutasteride showing the greatest reduction.

HGF combined with ADA is highly accurate for diagnosing tuberculous pleural effusion, especially in younger females.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

In this study, triamcinolone acetonide injections led to partial hair regrowth in 60% of alopecia totalis patients, suggesting potential benefits when followed by immunotherapy.

This study demonstrated that the Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata cases with high sensitivity and specificity in a dermatology clinic setting.

This study found that coadministration of tadalafil and finasteride improved lower urinary tract symptoms and erectile function in men with benign prostatic hyperplasia better than finasteride alone over 26 weeks.